» Articles » PMID: 36406312

The Gut Microbiome and Ferroptosis in MAFLD

Overview
Specialty Gastroenterology
Date 2022 Nov 21
PMID 36406312
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic-associated fatty liver disease (MAFLD) is a new disease definition, and is proposed to replace the previous name, nonalcoholic fatty liver disease (NAFLD). Globally, MAFLD/NAFLD is the most common liver disease, with an incidence rate ranging from 6% to 35% in adult populations. The pathogenesis of MAFLD/NAFLD is closely related to insulin resistance (IR), and the genetic susceptibility to acquired metabolic stress-associated liver injury. Similarly, the gut microbiota in MAFLD/NAFLD is being revaluated by scientists, as the gut and liver influence each other via the gut-liver axis. Ferroptosis is a novel form of programmed cell death caused by iron-dependent lipid peroxidation. Emerging evidence suggests that ferroptosis has a key role in the pathological progression of MAFLD/NAFLD, and inhibition of ferroptosis may become a novel therapeutic strategy for the treatment of NAFLD. This review focuses on the main mechanisms behind the promotion of MAFLD/NAFLD occurrence and development by the intestinal microbiota and ferroptosis. It outlines new strategies to target the intestinal microbiota and ferroptosis to facilitate future MAFLD/NAFLD therapies.

Citing Articles

From mechanisms to medicine: Ferroptosis as a Therapeutic target in liver disorders.

He Y, Lin Y, Song J, Song M, Nie X, Sun H Cell Commun Signal. 2025; 23(1):125.

PMID: 40055721 PMC: 11889974. DOI: 10.1186/s12964-025-02121-2.


Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD.

Termite F, Archilei S, DAmbrosio F, Petrucci L, Viceconti N, Iaccarino R Antioxidants (Basel). 2025; 14(1).

PMID: 39857390 PMC: 11759774. DOI: 10.3390/antiox14010056.


ABL1‒YAP1 axis in intestinal stem cell activated by deoxycholic acid contributes to hepatic steatosis.

Mao T, Xu X, Liu L, Wu Y, Wu X, Niu W J Transl Med. 2024; 22(1):1119.

PMID: 39707364 PMC: 11662811. DOI: 10.1186/s12967-024-05865-6.


Effects of Bifidobacterium and rosuvastatin on metabolic-associated fatty liver disease via the gut-liver axis.

Ran X, Wang Y, Li S, Dai C Lipids Health Dis. 2024; 23(1):401.

PMID: 39696288 PMC: 11654016. DOI: 10.1186/s12944-024-02391-8.


Ferroptosis as a potential connection between schizophrenia and metabolic dysfunction-associated steatotic liver disease - a narrative review.

Rogalski J, Tomczak T Postep Psychiatr Neurol. 2024; 33(3):178-187.

PMID: 39678457 PMC: 11635434. DOI: 10.5114/ppn.2024.142136.


References
1.
Polyzos S, Kountouras J, Mantzoros C . Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2018; 92:82-97. DOI: 10.1016/j.metabol.2018.11.014. View

2.
Hu H, Lin A, Kong M, Yao X, Yin M, Xia H . Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol. 2019; 55(2):142-158. PMC: 6981320. DOI: 10.1007/s00535-019-01649-8. View

3.
Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal W, Strowig T . Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482(7384):179-85. PMC: 3276682. DOI: 10.1038/nature10809. View

4.
Dubinkina V, Tyakht A, Odintsova V, Yarygin K, Kovarsky B, Pavlenko A . Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. Microbiome. 2017; 5(1):141. PMC: 5645934. DOI: 10.1186/s40168-017-0359-2. View

5.
Rahman K, Desai C, Iyer S, Thorn N, Kumar P, Liu Y . Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. Gastroenterology. 2016; 151(4):733-746.e12. PMC: 5037035. DOI: 10.1053/j.gastro.2016.06.022. View